Amgen's Repatha lowers heart attack risk 20% versus ezetimibe in real-world study

Bitget2026/11/05 14:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Amgen announced real-world study results showing Repatha lowered fatal or nonfatal heart attack risk compared with ezetimibe.
The study followed 544,103 adults with atherosclerotic cardiovascular disease and prior statin use for up to four years.
Results were published in the American Journal of Preventive Cardiology, providing comparative evidence to guide non-statin treatment choices.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amgen Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA89623) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Amgen's Repatha lowers heart attack risk 20% versus ezetimibe in real-world study

You may also like

Crypto prices